Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cance...
Advaxis, Inc. (ADXS)
Last advaxis, inc. earnings: 9/9 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.advaxis.com
Company Research
Source: Business Wire
Results Show Treatment of Tumor-Bearing Mice with Axalimogene Filolisbac (AXAL) Leads to Natural Killer Cell Activation and Other Important Immune-Related Effects PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC). The poster, entitled “Natural killer (NK) cells orchestrate the antitumor activities of Listeria monocytogenes (Lm)-based immunotherapy,” evaluated the impact of Lm-based immunotherapy on the activation of NK cells in a murine model of human papillomavirus (HPV)-associated tumors. Poster Number P520 will be presented by Sandy Hayes, Ph.D., Sr. Director, Research - BioMarkers and Immune Monitoring, on Saturday, November 10, 2018 from 12:20 – 1:50 p.m. and 7:00 – 8:30
Show less
Read more
Impact Snapshot
Event Time:
ADXS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADXS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADXS alerts
High impacting Advaxis, Inc. news events
Weekly update
A roundup of the hottest topics
ADXS
News
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Ayala Pharmaceuticals, Inc. (NASDAQ: ADXS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
ADXS
Sec Filings
- 4/19/24 - Form 8-K/A
- 4/16/24 - Form 10-K
- 4/15/24 - Form S-8
- ADXS's page on the SEC website